.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
UBS
Fish and Richardson
Farmers Insurance
McKesson
Accenture
Colorcon
QuintilesIMS
Federal Trade Commission
Medtronic

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202490

« Back to Dashboard
NDA 202490 describes RIZATRIPTAN BENZOATE, which is a drug marketed by Glenmark Pharms Ltd, Panacea Biotec Ltd, Cipla Ltd, Sandoz, Jubilant Generics, Unichem Labs Ltd, Invagen Pharms, Apotex Inc, Macleods Pharms Ltd, Eci Pharms Llc, Aurobindo Pharma Ltd, Teva Pharms, Glenmark Generics, Alkem Labs Ltd, Mylan Pharms Inc, Natco Pharma Ltd, and Emcure Pharms Ltd, and is included in twenty-five NDAs. It is available from twenty-six suppliers. Additional details are available on the RIZATRIPTAN BENZOATE profile page.

The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

Summary for NDA: 202490

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antimigraine Agents

Pharmacology for NDA: 202490

Suppliers and Packaging for NDA: 202490

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET;ORAL 202490 ANDA Citron Pharma LLC 57237-087 57237-087-34 4 BLISTER PACK in 1 CARTON (57237-087-34) > 3 TABLET in 1 BLISTER PACK
RIZATRIPTAN BENZOATE
rizatriptan benzoate
TABLET;ORAL 202490 ANDA Citron Pharma LLC 57237-087 57237-087-63 3 BLISTER PACK in 1 CARTON (57237-087-63) > 6 TABLET in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Dec 31, 2012TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Dec 31, 2012TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Accenture
Deloitte
Colorcon
Moodys
Boehringer Ingelheim
Johnson and Johnson
Argus Health
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot